Verve Therapeutics (VERV) News Today $4.97 +0.85 (+20.63%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$4.95 -0.02 (-0.40%) As of 07:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period J.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)April 16 at 6:03 AM | markets.businessinsider.comVerve Therapeutics (NASDAQ:VERV) Given New $24.00 Price Target at GuggenheimApril 16 at 3:49 AM | americanbankingnews.comCanaccord Genuity Group Issues Positive Forecast for Verve Therapeutics (NASDAQ:VERV) Stock PriceApril 16 at 3:49 AM | americanbankingnews.comVerve extends gains as Cantor Fitzgerald upgrades on data for cholesterol drugApril 15 at 8:02 PM | msn.comVerve Therapeutics price target raised to $24 from $18 at GuggenheimApril 15 at 8:02 PM | markets.businessinsider.comCantor upgrades Verve Therapeutics to Overweight after positive dataApril 15 at 8:02 PM | markets.businessinsider.comWhy Verve Therapeutics Is Skyrocketing TodayApril 15 at 1:20 PM | fool.comVerve Therapeutics price target raised to $25 from $15 at H.C. WainwrightApril 15 at 4:14 AM | markets.businessinsider.comVerve jumps after early-stage trial data for gene editing therapyApril 14 at 11:13 PM | msn.comVerve’s second swing at gene editing for heart disease shows early promiseApril 14 at 11:13 PM | finance.yahoo.com6VERV : Assessing Verve Therapeutics:...April 14 at 11:13 PM | benzinga.comVerve’s shares jump by more than 26% on Lilly-partnered gene therapy dataApril 14 at 11:13 PM | finance.yahoo.comThis Cholesterol Gene Medicine Could Work in 1 Shot. It Could Also Bring This Biotech Stock Back to Life.April 14 at 11:13 PM | msn.comVerve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single DoseApril 14 at 12:03 PM | benzinga.comVerve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9April 14 at 7:00 AM | globenewswire.comNorges Bank Purchases Shares of 78,186 Verve Therapeutics, Inc. (NASDAQ:VERV)Norges Bank acquired a new position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 78,186 shares of the company's stock, valued at approximatApril 14 at 3:29 AM | marketbeat.comVerve Therapeutics receives FDA Fast Track designation for VERVE-102April 11, 2025 | markets.businessinsider.comVerve Therapeutics Gets FDA Fast-Track Designation for Verve-102April 11, 2025 | marketwatch.comVerve Therapeutics wins FDA fast track status for cholesterol treatmentApril 11, 2025 | msn.comVerve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9April 11, 2025 | globenewswire.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Trexquant Investment LPTrexquant Investment LP raised its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 14.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 635,847 shares of the company's stock after purchasing an additiApril 8, 2025 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Joan Nickerson Sells 2,777 SharesVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Joan Nickerson sold 2,777 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a total transaction of $11,524.55. Following the transaction, the insider now owns 17,420 shares in the company, valued at $72,293. The trade was a 13.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.April 5, 2025 | marketbeat.comAllison Dorval Sells 3,350 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) StockVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) CFO Allison Dorval sold 3,350 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $4.15, for a total transaction of $13,902.50. Following the completion of the transaction, the chief financial officer now directly owns 13,280 shares of the company's stock, valued at approximately $55,112. The trade was a 20.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.April 5, 2025 | marketbeat.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Sells $11,524.55 in StockApril 4, 2025 | insidertrades.comIs Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?April 2, 2025 | finance.yahoo.com8 Best Gene-Editing Stocks to BuyApril 2, 2025 | insidermonkey.comIs Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?April 1, 2025 | insidermonkey.comWilliam Blair Sticks to Its Buy Rating for CAMP4 Therapeutics Corporation (CAMP)March 28, 2025 | markets.businessinsider.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Buy" by AnalystsShares of Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) have earned an average rating of "Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price taMarch 26, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Given "Buy" Rating at GuggenheimGuggenheim reiterated a "buy" rating on shares of Verve Therapeutics in a research note on Tuesday.March 26, 2025 | marketbeat.comVerve Therapeutics' (VERV) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $15.00 price target on shares of Verve Therapeutics in a report on Tuesday.March 26, 2025 | marketbeat.comVerve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 CatalystsMarch 25, 2025 | seekingalpha.comWilliam Blair Remains a Buy on Verve Therapeutics (VERV)March 25, 2025 | markets.businessinsider.comVerve Therapeutics announces FDA clearance of IND application for VERVE-102March 24, 2025 | markets.businessinsider.comVerve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single DoseMarch 24, 2025 | globenewswire.comVerve Therapeutics (NASDAQ:VERV) Trading Down 6.2% - What's Next?Verve Therapeutics (NASDAQ:VERV) Shares Down 6.2% - Here's What HappenedMarch 19, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Down 11% - What's Next?Verve Therapeutics (NASDAQ:VERV) Stock Price Down 11% - Should You Sell?March 11, 2025 | marketbeat.comMutated DNA Restored to Normal in Gene Therapy AdvanceMarch 10, 2025 | nytimes.comWilliam Blair downgrades Neumora Therapeutics, Inc. (NMRA) to a HoldMarch 7, 2025 | markets.businessinsider.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Down on Analyst DowngradeVerve Therapeutics (NASDAQ:VERV) Shares Gap Down Following Analyst DowngradeMarch 5, 2025 | marketbeat.comRoyal Bank of Canada Issues Pessimistic Forecast for Verve Therapeutics (NASDAQ:VERV) Stock PriceRoyal Bank of Canada reduced their target price on Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday.March 5, 2025 | marketbeat.comVerve Therapeutics price target lowered to $15 from $17 at RBC CapitalMarch 4, 2025 | markets.businessinsider.comAnalysts Set Expectations for VERV Q1 EarningsVerve Therapeutics, Inc. (NASDAQ:VERV - Free Report) - William Blair issued their Q1 2026 earnings per share (EPS) estimates for Verve Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Minter expects that the company will post earnings of ($0.77) perMarch 3, 2025 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, HC Wainwright Analyst SaysHC Wainwright upped their price target on Verve Therapeutics from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday.March 1, 2025 | marketbeat.comVerve Therapeutics price target raised to $15 from $14 at H.C. WainwrightMarch 1, 2025 | markets.businessinsider.comVerve Therapeutics (NASDAQ:VERV) Releases Earnings Results, Beats Estimates By $0.14 EPSVerve Therapeutics (NASDAQ:VERV - Get Free Report) announced its earnings results on Thursday. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%.February 28, 2025 | marketbeat.comVerve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2February 28, 2025 | seekingalpha.comVerve Therapeutics Full Year 2024 Earnings: Beats ExpectationsFebruary 28, 2025 | finance.yahoo.comVertex ends gene editing research pact with VerveFebruary 27, 2025 | finance.yahoo.com Remove Ads Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Media Mentions By Week VERV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼0.630.79▲Average Medical News Sentiment VERV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼236▲VERV Articles Average Week Remove Ads Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARS Pharmaceuticals News Today Disc Medicine News Today Vera Therapeutics News Today Mesoblast News Today Immunocore News Today Travere Therapeutics News Today Indivior News Today Edgewise Therapeutics News Today Ocular Therapeutix News Today Calliditas Therapeutics AB (publ) News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERV Stock Free VERV Stock Alerts